Commercial molecular diagnostics in the U.S.: The human genome project to the clinical laboratory

Human Mutation

Volumn 19, Issue 4, 2002, Pages 324-333

  Amos, Jean ^a   Patnaik, Meeta ^a  

^a Specialty Laboratories   (United States)

Author keywords

Clinical genetics; Genetic testing; Intellectual property; Molecular diagnostics; Mutation detection; SNP

Indexed keywords

DNA; RNA;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL LABORATORY; COST BENEFIT ANALYSIS; DIAGNOSTIC KIT; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOMICS; GOOD LABORATORY PRACTICE; HUMAN; PRIORITY JOURNAL; RELIABILITY; REVIEW; UNITED STATES;

DIAGNOSTIC TESTS, ROUTINE; DNA MUTATIONAL ANALYSIS; GENETIC SCREENING; GENETICS, MEDICAL; HUMAN GENOME PROJECT; HUMANS; INTELLECTUAL PROPERTY; MOLECULAR BIOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036198528     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.10061     Document Type: Review

References (26)

1. Fragile X syndrome: Diagnostic and carrier testing. Working group of the genetic screening subcommittee of the clinical practice committee
2. Working group on ApoE and Alzheimer disease statement on use of apolipoprotein E testing for Alzheimer disease
3. Screening for canavan disease. Committee opinion, No. 212
4. Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents
5. Diagnostic testing for Prader-Willi and Angelman syndromes: Report of the ASHG/ACMG test and technology transfer committee
6. Testing environment for single gene disorders in U.S. reference laboratories
7. Hemochromatosis
8. Mutation detection 2001: Sixth international symposium on mutations in the human genome, May 3-7, 2001
9. DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: Correspondance with melting theory
10. Newborn screening for cystic fibrosis in Wisconsin: Comparison of biochemical and molecular methods
11. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening
12. American college of medical genetics consensus statement on factor V Leiden mutation testing
13. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy
14. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel
15. A novel mutation in the cystic fibrosis gene with pulmonary disease but normal sweat chloride concentration
16. Initial sequencing and analysis of the human genome
17. Antenatal diagosis of sickle-cell anaemia by D.N.A. analysis of amniotic fluid cells
18. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease
19. Identification of the cystic fibrosis gene: Genetic analysis
20. Technical standards and guidelines for fragile X: The first of a series of diseasespecific supplements to the standards and guidelines for clinical genetics laboratories of the American college of medical genetics. Quality assurance subcommittee of the laboratory practice committee
21. Genetic testing: Families sue hospital, scientist for control of Canavan gene
22. A rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction
23. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
24. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
25. Identification of the cystic fibrosis gene: Chromosome walking and jumping